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Abstract
Background: Although tuberculosis is transmitted by the airborne route, direct information on the natural output of bacilli
into air by source cases is very limited. We sought to address this through sampling of expelled aerosols in face masks that
were subsequently analyzed for mycobacterial contamination.
Methods: In series 1, 17 smear microscopy positive patients wore standard surgical face masks once or twice for periods
between 10 minutes and 5 hours; mycobacterial contamination was detected using a bacteriophage assay. In series 2, 19
patients with suspected tuberculosis were studied in Leicester UK and 10 patients with at least one positive smear were
studied in The Gambia. These subjects wore one FFP30 mask modified to contain a gelatin filter for one hour; this was
subsequently analyzed by the Xpert MTB/RIF system.
Results: In series 1, the bacteriophage assay detected live mycobacteria in 11/17 patients with wearing times between 10
and 120 minutes. Variation was seen in mask positivity and the level of contamination detected in multiple samples from
the same patient. Two patients had non-tuberculous mycobacterial infections. In series 2, 13/20 patients with pulmonary
tuberculosis produced positive masks and 0/9 patients with extrapulmonary or non-tuberculous diagnoses were mask
positive. Overall, 65% of patients with confirmed pulmonary mycobacterial infection gave positive masks and this included
3/6 patients who received diagnostic bronchoalveolar lavages.
Conclusion: Mask sampling provides a simple means of assessing mycobacterial output in non-sputum expectorant. The
approach shows potential for application to the study of airborne transmission and to diagnosis.
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Introduction
Tuberculosis (TB) remains a major global health problem with
8.6 million new cases in 2012 [1]. The causal agent, Mycobacte-
rium tuberculosis, is an obligate pathogen that is dependent on
airborne transfer to new hosts for its long-term survival [2].A
better understanding of the mechanisms involved in M. tubercu-
losis transmission offers the potential to improve public health
practice and is urgent given the rising numbers of multidrug
resistant (MDR) and extensively drug-resistant (XDR) strains [1].
Sputum has been the principal sample type used for microbi-
ological diagnosis of TB [3] and enumeration of acid fast bacilli
(AFB) therein has been used to assess case infectivity [4].
In early studies at the turn of the 19th and 20th centuries there
was discussion of the relative roles of dried sputum dispersed as
dust, large droplets and fine sprays together with contamination of
food as key pathways for the spread of TB (reviewed in [5]). It was
over fifty years later that Wells, Riley and colleagues directly
demonstrated the importance of aerosolized fine droplet nuclei (,
5 mm) in TB transmission [6], a view that has been further
substantiated in recent airborne transmission studies [7–8].
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However, relatively little is known about the formation of these
bacteria-containing aerosols.
While it is generally assumed in clinical practice that sputum
smear positive cases are the predominant sources of infection, it is
self-evident that mucus-enveloped bacilli in expectorated and
macroscopically visible sputum do not mediate transmission.
Moreover, several recent epidemiological and experimental studies
highlight the degree to which sputum positivity does not correlate
with detected transmission [9–12].
Analytical methods that assess output of bacilli in expelled
aerosols from M. tuberculosis infected individuals are clearly
needed to enable us to investigate the mechanism of TB
transmission in detail. Guinea pig infection studies in clinical
facilities clearly support the possibility of droplet nuclei-based
transfer over extended distances [6–8]. However, the feasibility of
relating patient and bacterial characteristics at the time when the
infectious dose is expelled to individual transmission events is very
limited due to the time delay between infection and its detection in
the animals. In contrast, the studies of Fennelly and colleagues
have focused on output of colony-forming units (cfu) of M.
tuberculosis in aerosols produced during brief and supervised
periods of deliberate coughing [12–14]. These investigators have
used the Cough Aerosol Sampling System (CASS) to provide
important new insights into the characteristics of aerosols
containing M. tuberculosis cfu and the relationships between
individual patient CASS results and transmission. In the present
context we note that, while there was a positive correlation
between sputum AFB score and CASS cfu counts, the majority of
AFB-positive subjects did not produce culturable aerosols and
there was a tendency for patients with salivary and muco-salivary
sputum samples to be aerosol cfu positive [12]. These features
emphasise uncertainties in our understanding of the relationships
between sputum and infectious aerosols.
While the CASS approach provides a single time point
assessment of M. tuberculosis cfu counts in aerosols it requires
significant infrastructure and carefully balanced apparatus to
obtain valid samples. Moreover, the capacity of CASS to
determine potentially critical assessments of TB case infectivity
such as total daily output of M. tuberculosis and diurnal variations
in output, and to achieve these analyses in settings comparable to
normal daily life, are very limited.
To address these issues, we have been exploring the potential of
using face masks to collect and assess expelled aerosol output from
both suspected and diagnosed cases of TB. We report here our
experience with mask collections from 46 individuals in different
settings and mycobacterial detection achieved first by bacterio-
phage assay then with the GeneXpert system. At present sampling
does not exclude contribution of.5 mm droplets to mask
contamination. Our findings show that mask sampling can readily
be used to detect M. tuberculosis contamination in expelled
aerosols and that the approach offers potential both for the study
of M. tuberculosis transmission and for the enhancement of
microbiologic diagnosis.
Materials and Methods
Patients
Subjects were recruited in two series, first in Leicester (Series 1;
2007–9) then both in Leicester and in The Gambia (Series 2;
2013). Series 1 samples were collected using unmodified standard
surgical masks and analyzed by bacteriophage assay. Series 2
samples were collected in rigid protective masks modified to
include a filter that was subsequently processed through the
Cepheid GeneXpert system.
All patients were $18 years and enrolled following informed
consent within formation provided in their preferred language.
Leicester patients were recruited though our local TB clinics,
Infectious Diseases Unit and Respiratory wards at University
Hospitals of Leicester NHS trust under National Research Ethics
Service approval (07/Q2501/58). Gambian patients were recruit-
ed from Health Centres associated with the UK Medical Research
Council (MRC) Unit in Fajara under approval SCC1343 from
The Gambia Government and MRC Joint Ethics Committee. In
all cases patients provided written consent following procedures
specifically approved by the two ethics governance systems.
Series 1. Between June 2007 and March 2009, we recruited
17 patients with AFB smear positive sputum. All patients had
positive confirmatory MGIT liquid cultures. Subjects were asked
to wear the mask for as long as they felt comfortable with a
recommended minimum of 1 hour; actual wearing times ranged
from 10–300 minutes. They were instructed to talk, sneeze and
cough as they wished. However, if they needed to expel sputum,
they were asked to briefly remove the mask away and spit into the
sputum pot provided. With the exception of 3 samples, all masks
were collected after chemotherapy had begun (within 7 days).
Series 2. Between February and June 2013, 20 subjects were
recruited in Leicester and 10 in The Gambia. Patients in Leicester
were recruited on the basis of a high clinical or radiological
suspicion of pulmonary TB while those in The Gambia all had at
least one sputum microscopy positive for AFB prior to mask
wearing. All wore filter containing masks for 1 hour. Instructions
were as for the phage analyzed group except that if they did not
make any vocal effort during this hour they were asked to cough
once and repeat ‘Peter’ ten times. All samples were taken prior to
starting TB treatment with the exception of 2 Leicester patients
who were sampled on day 5. An additional sputum sample was
taken from Gambian subjects during or after mask sampling and
this was stained for AFB and subjected to MGIT culture.
Analysis of Series 1 Samples – Surgical Masks and Phage
Assay
This was a developmental and exploratory phase and two types
of assay were used. For the first 9 patients mycobacteria released
from the mask by vortexing were directly assayed (Released
Bacteria (RB) assay). For the remaining 8 patients phage infection
On Mask (OM) assay was performed on the retained bacteria.
Flow charts outline the procedures for the two phage assays in
Figure 1. It should be noted that the phage assay detects both M.
tuberculosis complex and Non-Tuberculous Mycobacteria (NTM).
Pleat-style masks (Kimberly-Clark surgical 48105 or procedure
47085) were used for sampling. Once worn, the mask was folded
into quarters with the sampling surface facing inwards and placed
into a sterile 250-ml plastic jar. Mask samples were stored at 4uC if
not processed on the day of sampling. Details of the processing for
the RB, OM and phage assays are given in Methods S1.
Analysis of Series 2 samples –Modified masks and
GeneXpert assay
FFP30 face masks (MB Filter products, Mark 30) were modified
by cutting a 5.5 cm square opening from the center, into which an
equivalent sized gelatin membrane (3 mm pore size, Sartorius UK)
was attached in a custom-made detachable plastic holder secured
with autoclave tape (Figure 2).Each mask was stored in a sterile re-
sealable plastic bag which was then stored in a plastic container for
no more than 5 days before being used. After sampling, the mask
was placed and re-sealed into the plastic bag and plastic container
and stored at -70uC until DNA extraction and PCR analysis. For
Mask Sampling in Tuberculosis
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104921
analysis the filter membrane was removed from the mask, divided
into 3 pieces and dissolved in 4 ml of molecular grade water
(Invitrogen). This was then heated to 95uC for 10 minutes to
ensure the membrane was completely dissolved. 2 ml of the
dissolved filter was then transferred to a 2 ml micro-centrifuge
tube and centrifuged at 10,000xg for 10 minutes. The supernatant
was then removed and discarded and the pellet re-suspended in
1 ml of molecular grade water. This was then transferred into a
30 ml universal container to which 2 ml of the Xpert MTB/RIF
sample reagent (Cepheid) was added, shaken to mix and incubated
at room temperature for 15 minutes, shaking once again after 8
minutes. 2 ml of the mixture was then loaded into Xpert MTB/
RIF cassettes and loaded into the GeneXpert machine and
analyzed according to the manufacturer’s instructions [15].
Results
Preliminary studies
We first explored the potential to detect mask contamination by
M. tuberculosis-directed PCR [16] by inoculating masks with
cultured bacteria. We found that extracts from the surgical masks
used in series 1 were strongly inhibitory to amplification with a
detection limit of ,104 colony forming units (cfu) per mask (data
not shown) and the approach was abandoned and the phage assay
developed. In contrast, in series 2, extracts from gelatin
membranes showed little or no inhibitory activity in the same
assay with a detection limit of 102–3 cfu per membrane and this
provided the basis for developing the GeneXpert assay.
Series 1: Phage assays detect live bacilli on masks
Seventeen patients with at least one AFB positive sputum
sample were recruited. Of these, 10 were male, 7 female, the
average age was 40 years (18–70).One patient had concomitant
HIV infection. All 17 had sputum culture confirmed infection, two
with NTM (M. kansasii, patient 5; M. avium, patient 14) and the
remaining 15 with M. tuberculosis.
The plaque assay results are summarized in table 1. On patients
1–9, we trialed a method in which mycobacterial cells were
released from mask segments by vortexing then detected by phage
assay (RB assay, see figure 1). This method gave positive
mycobacterial detection on 8 occasions on samples from 6
patients. Assuming each plaque represented a single mycobacterial
cell, the RB method yielded between 4 and 32 detected
mycobacteria per mask (data not shown).
In an effort to improve assay sensitivity we explored the value of
applying phage D29 directly to contaminated masks. To our
surprise, we found that this appeared to be an effective means of
releasing mycobacterial cells from the mask and pfu counts well in
excess of control values were readily obtained (OM assay, see
figure 1). We also determined that decontamination with NaOH/
NALC reduced counts by at least 3-fold (data not shown) and that
assay contamination could be prevented with the combination of
nystatin, oxacillin and aztreonam (NOA) recommended by Mole
and colleagues [17].
The OM assay gave positive mycobacterial detection in 9 of the
thirteen masks assessed and in 5 of the 8 patients. The pfu counts
indicated between 6,000 and 32,000 mycobacteria per mask (data
not shown).
Overall, the phage methods gave positives in 11/17 (65%)
patients, all of who had clinically and microbiologically diagnosed
pulmonary disease. These included two cases of NTM infection.
The phage employed in our assays (D29) infects most mycobac-
terial species. Two masks were collected in 11 patients and
discordant results (one positive one negative) were found in two
cases (patients 4 and 5). Considerable variation in pfu counts was
also seen when both samples were positive (6 patients; data not
shown).
Series 2: GeneXpert detects contamination of mask filter
inserts in Leicester and Gambian patients
In Leicester, 20 patients with high clinical/radiological suspi-
cion of pulmonary TB were recruited (12 males and 8 females).
Average age was 39 (19–69). All were HIV negative.
Figure 1. Schematic of mask processing for phage assay. See
text for abbreviations.
doi:10.1371/journal.pone.0104921.g001
Figure 2. FFP30 mask with filter adapted for sampling.
doi:10.1371/journal.pone.0104921.g002
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One patient was excluded from analysis due to a processing
error signaled by the GeneXpert instrument so that no result could
be obtained. Of the remaining 19 patients, 10 (53%) were
diagnosed with pulmonary TB by the consultant physician and
commenced on TB treatment. Physicians were not aware of the
mask result at the time of diagnosis. A further 3 patients were
found to have extra-pulmonary TB, two with TB lymphadenitis
and one with pleural TB, and were also commenced on TB
treatment. All were notified. An alternative diagnosis was made in
the remaining six patients (32%).
Of the 10 patients diagnosed with pulmonary TB, 6 were mask
positive and four were mask-negative. No rifampin resistance was
detected. Mask samples were negative for all patients with extra-
pulmonary TB and non-TB diagnoses (Table 2).
In the course of their clinical investigation, five patients were
unproductive of sputum and a total of six patients had
bronchoalveolar lavage aspirate samples collected to aid diagnosis.
80% (4 out of 5) of patients with a smear positive sputum result
also had a mask positive result, whereas 2 out of 5 (40%) of those
with an unproductive cough and a diagnosis of pulmonary TB had
a mask positive result.
Sputum samples from 2 patients with GeneXpert positive mask
samples failed to grow any mycobacterium in culture but a
confident clinical diagnosis of TB was made. Patient 19 gave one
scanty AFB positive sputum smear but remained negative by
repeated culture and GeneXpert analyses applied to sputum.
Patient 27 was unproductive of sputum with negative results for
BAL aspirate, AFB smear and culture.
In the Gambia, 10 patients with an initial positive AFB smear
were recruited. Eight patients were male, 2 female and their
average age was 32 years (23–49). All patients were Black African,
were of unknown HIV status, had a confident clinical diagnosis of
pulmonary TB and were commenced on treatment. Seven patients
had a positive mask sample. Patient 38 had 3 AFB positive smears
prior to recruitment, however, the additional post-recruitment
Table 1. SERIES 1, PHAGE ASSAYS ON SURGICAL MASKS.
Patient No. am/pm Sample Sampling Period (min) Phage Assay `
1 am 300 -
1 pm 120 -
2 pm 120 -
3 U 10 +
3 U U +
4 U 60 -
4 U 60 +
5* am 30 +
5 pm 30 -
6 am 120 +
7" U 50 +
7 U 25 +
8 U 40 -
9" U 60 +
10" am 30 -
10 pm 50 -
11 U U -
12 pm 40 +
13 am 60 +
13 pm 60 +
14{ am 60 +
14 pm 60 +
15 am 60 +
15 pm 60 +
16 am 45 +
16 pm 45 +
17 am 30 -
17 pm 30 -
ND= not done; U = not recorded.
*M. kansasii isolated.
{M. aviumisolated.
`Patients 1–9 - RB assay; 10–17 – OM assay.
"Pre-chemotherapy samples.
doi:10.1371/journal.pone.0104921.t001
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sputum was negative for both microscopy and MGIT; nonetheless,
his mask was positive by GeneXpert.
In summary, of the 20 patients with clinically confirmed
pulmonary TB assessed by analysis of mask filter inserts assayed by
GeneXpert, 13 (65%) gave at least one positive mask. In 6 patients
who had diagnostic BALs performed because suspicion of TB was
high and they either did not produce sputum or this was negative,
3 gave positive filters and in one of these the BAL was negative on
smear and culture. In addition, no false positives were obtained
from six patients who were found to have diagnoses other than TB
or from the 3 patients with extra-pulmonary TB.
Combining the phage and GeneXpert assays, mask sampling
gave unambiguous evidence that infected patients expelled
significant numbers of mycobacteria in aerosols in 24 out of 37
(65%) cases of pulmonary infection.
Discussion
We have demonstrated the successful detection of M. tubercu-
losis and NTM species expectorated by patients with pulmonary
disease using direct mask sampling. Masks have been shown to be
contaminated with both live bacilli (phage assay) and with
extractable M. tuberculosis DNA. Detection of the latter with
the GeneXpert system potentially makes our approach available to
many laboratories worldwide.
Until recently we were aware of only one previous report of
mask sampling in which the RNA of respiratory viruses was
detected [18]. However, our attention has been drawn to the
fascinating earlier studies of L Napoleon Boston who reported in
1901 use of a face mask device in which expelled aerosols were
collected on microscope slides[5]. We allude to this study further
below.
Table 2. GeneXpert ASSAY APPLIED TO FILTER INSERTS.
Clinical Diagnosis Patient No. Mask GeneXpert AFB Smear` Culture
Pulmonary TB (UK n = 10) 18 + Sp+++ Sp +
19 + Sp SC Sp -
20 + Sp+++ Sp +
21 - Sp SC Sp +
22{ + BAL- BAL +
23 - BAL++ BAL +
24 - BAL- BAL +
25 + Sp- Sp -
BAL- BAL +
26 - BAL- BAL +
27 + BAL- BAL -
Extrapulmonary* (UK n= 3) 28 - LN- LN +
29{ - PA - PA +
30 - LN - LN +
Non-TB (UK n = 6) 31 - Sp - Sp -
32 - Sp - ND
33 - Sp - Sp -
34 - Sp - Sp -
35 - Sp - Sp -
36 - Sp - Sp -
Pulmonary TB (Gambia n= 10) 37 - Sp - Sp +
38 + Sp - Sp -
39 + Sp+++ Sp +
40 + Sp++ Sp +
41 - Sp+ Sp +
42 + Sp+++ Sp +
43 + Sp+ Sp +
44 + Sp+++ Sp +
45 + Sp SC Sp +
46 - Sp - Sp +
BAL = bronchoalveolar lavage; LN= lymph node aspirate, PA = pleural aspirate, Sp = sputum, SC = scanty, ND= Not done.
`UK Smear result from local diagnostic service, Gambia smear result from MRC lab. All Gambian patients had a prior smear-positive from their local health clinic.
*All patients diagnosed with extrapulmonary TB were sputum smear- and culture-negative.
{Mask collected day 5 of TB treatment.
doi:10.1371/journal.pone.0104921.t002
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In Series 1 the phage assay detected both M. tuberculosis and
NTM with mask exposure times ranging from 10 minutes to
2 hours; at the other end of the spectrum, one patient did not
produce phage detectable mask contamination after 5 hours
exposure (Patient 1, table 1). Although we are confident that we
detected variations in mycobacterial contamination of expelled
aerosols at different time points, we only report positive and
negative mycobacterial detection here since we have not
specifically validated the phage assays for quantitation. However,
it does appear that the OM assay was more sensitive than the RB
assay and we found pfu counts indicating contamination rates of
masks compatible with 104–5 bacilli per hour (data not shown).
Due to the small sample size and the uncertain timings of several
samples we cannot draw firm conclusions concerning time of day
of sampling and positive mask contamination, though morning
samples have marginally more positive phage assays than
afternoon samples.
In Series 2 we developed a simple rapid method in which gelatin
filters incorporated into masks were exposed to expelled aerosols
and subjected to GeneXpertMTB/RIF analysis. This approach
gave M. tuberculosis positive filters in 13/20 pulmonary TB
patients.
Regarding our primary purpose to establish a method for
sampling M. tuberculosis output in expelled aerosols, mask
sampling provides a simple, potentially continuous, non-invasive
approach that can be used to better define the pattern of
expectoration in many individuals. The phage assay demonstrated
the presence of live bacilli while the molecular assay links to a
widely available and WHO recommended platform. We have not
sought to validate quantitative mask analyses here because the
expiratory efforts of our subjects were not well-standardized and
our sample size was small. However, we are confident that this can
be achieved. We note mask positivity rates of 65% in both series 1
and 2 and this compares with CASS positivity rates of 25 [14],
27.7 [13]and 45% [12]. It is not surprising that the more extended
sampling used here leads to higher positive rates but we emphasize
that the mask approach could allow the natural pattern of output
to be studied. In contrast, the CASS approach probes the capacity
of an individual to produce an infectious aerosol only at a single
time-point.
By sampling expelled aerosols, masks incorporate both aerosol
and large (.5 mm) droplets. Combining daily mask output with
sputum output should allow estimation of the total number of
bacilli expectorated per day. Given the recent recognition of
multiple M. tuberculosis phenotypes in sputum and indications
that many bacilli are not replicating [19,20], combined mask and
sputum enumeration could facilitate insight into the pattern of
intrapulmonary replication necessary to achieve the observed
output.
It is widely accepted that production of M. tuberculosis
contaminated droplet nuclei is the principal mode of transfer to
the lungs of a new host. Whether or not the mixed droplet and
aerosol assessment achieved by mask sampling will undermine the
capacity to relate results to transmission is yet to be determined.
However, droplet mediated transmission of TB to intimate
contacts cannot be excluded. This mode of transmission contrib-
utes to a number of upper and lower respiratory tract infections
[21–23] and we are not aware of data ruling this out in TB. While
it seems likely that fine aerosols are responsible for most
transmission, the specific relationship between large and fine
aerosols of M. tuberculosis, to our knowledge, has not been
studied. Since humans produce a wide range of aerosol particle
sizes [24], the mask sampling approach may offer a useful tool to
study the relationship between expelled aerosols of all sizes and
infectivity. The approach is also amenable to refinement in the
filter capture system such that some degree of droplet/aerosol
discrimination is possible.
In a diagnostic context, the numbers of patients and controls
studied here are insufficient to make formal estimates of sensitivity
and specificity. However, using clinical diagnosis of pulmonary TB
for comparison, we have no evidence of false positives in either
series. With the design shown in figure 2, care would be needed to
exclude exogenous contamination in high burden settings partic-
ularly when masks are worn in the home environment. This could
be achieved by covering the external surface of the filter and by
strict instructions regarding storage. Regarding false negativity,
seven of 20 mask samples in series 2 were negative in patients
whose diagnosis was confirmed by culture. To improve the
sensitivity of mask sampling for diagnosis there is clear scope to
increase sampling times and apply a more sensitive molecular
assay [25,26].
We obtained positive masks from 3 of 6 patients in whom BAL
sampling was performed. This raises the possibility that mask
sampling might obviate the need for this costly and invasive
procedure in some cases. In resource poor settings where BAL
sampling is not performed, mask sampling may offer an alternative
diagnostic tool for smear negative or non-productive patients.
Limitations of the study
In addition to the relatively small sample size, interpretation of
our results is limited by the developmental nature of the work
leading to evolving methodologies and differing inclusion criteria.
There is much scope with this approach to determine the optimum
duration and time of day for sampling as well as defining or
monitoring the expiratory effort associated with each sample. We
have also noted that a formal study designed to determine
diagnostic value would need to take precautions regarding
potential exogenous contamination. Further developments could
focus on optimizing the sensitivity and quantitative aspects of the
molecular assay.
Finally, relating our results to the studies of L Napoleon Boston
[5], he reported that 38 of the 50 pulmonary patients he studied
yielded slides positive for tubercle bacilli detected by carbol-
fuchsin staining with exposure times of 1–1.5 hours; the study was
organized ‘‘with the object being not to collect on the slide the
spray produced by vigorous coughing’’. He comments that ‘‘In
fully one-third of positive cases the bacilli were very numerous’’.
Regarding the negative slides, he notes that 7 of these related to
patients with paucibacillary contemporaneous sputum samples.
Given that more than a century separates our studies and the very
likely advanced pathology in pre-chemotherapy patients, the
correspondence in positivity rates of 76 and 65% respectively for
Boston and the present study is intriguing. Moreover, the low
sensitivity of microscopy for detecting bacilli makes it all the more
remarkable that such a high frequency of positives was obtained.
Indeed, many of his patients seem to have expelled aerosols
contaminated at the highest levels we have estimated.In summary,
mask sampling is a simple and amenable approach to monitoring
respiratory output of infectious particles. Samples can be subjected
to biological or molecular assays and the approach has potential to
serve both research and diagnostic applications.
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